Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: A meta-analysis

Minerva Chirurgica

Volumn 70, Issue 6, 2015, Pages 451-458

  Hu, W ^a   Xu, W S ^a   Liao, X F ^a   He, H J ^a  

^a Department of Oncological Radiotherapy   (China)

Author keywords

Bevacizumab; Colorectal neoplasms neoplasm metastasis; Disease free survival; Survival

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB;

COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY; SURVIVAL ANALYSIS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84962497623     PISSN: 00264733     EISSN: 18271626     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Chen W. Cancer statistics: updated cancer burden in China. Chin J Cancer Res 2015;27:1.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
4. Wozniak AJ, Moon J, Thomas CR Jr, Kelly K, Mack PC, Gaspar LE et al. a pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage iii non-small-cell lung cancer: SWOG S0533. Clin Lung Cancer 2015; pii:S1525-7304:00003-0.
5. Cao D, Guo CH, Liu JW, Yang X, Li Q. Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer. Tumori 2015;0:0.
6. Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF et al. Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res 2015 [Epub ahead of print].
7. Liu Y, Starr MD, Brady JC, Rushing C, Bulusu A, Pang H et al. Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus. Mol Cancer Ther. 2015;14:1048-56.
8. Patel SR, Karnad AB, Ketchum NS, Pollock BH, Sarantopoulos J, Weitman S et al. Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. J Gastrointest Oncol 2014:99-103.
9. Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y et al. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol [Epub ahead of print].
10. Duran AO, Karaca H, Besiroglu M, Bayoglu IV, Menekse S, Yapici HS et al. XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev 2014;15:10375-9.
11. Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N et al. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. Pharmacoeconomics 2015 [Epub ahead of print].
12. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al. Bevacizumab in combination withoxaliplatin-based chemotherapy as first-line therapy in metastaticcolorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
13. Jadad ARI, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996;17:11-2.
14. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705.
15. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
16. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:369737-705.
17. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010;28:3191-8.
18. Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios S, Stathopoulos J et al. Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study. Oncology 2010;78:376-81.
19. Guan ZZ, Xu JM, Luo RC, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011;30:682-9.
20. Chen W, Zheng R, Zeng H, Feng FY, Wang LW, Shen L et al. Annual report on status of cancer in China, 2011. Chin J Cancer Res 2015;27:2-12.
21. Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ et al. A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer. Clin Colorectal Cancer 2015;14:1-10.
22. Dattatreya S. Metastatic colorectal cancer-prolonging overall survival with targeted therapies. South Asian J Cancer 2013;2:179-85.
23. Ichihara E, Hotta K, Nogami N, Kuyama S, Kishino D, Fujii M et al. Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol 2015;10:486-91.
24. Lukas RV, Gabikian P, Garza M, Chmura SJ. Treatment of brain metastases. Oncology 2014;87:321-9.
25. Varol U, Yildiz I, Salman T, Karabulut B, Uslu R. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer. Tumori 2014;100:370-6.
26. Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF et al. First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis. J Clin Oncol 2015;33:1112-8
27. Bria E, Gralla RJ, Raftopoulos H, Giannarelli D. Comparing two methods of meta-analysis in clinical research-individual patient data-based (IPD) and literaturebased abstracted data (AD) methods: analyzing five oncology issues involving more than 10, 000 patients in randomized clinical trials (RCTs). J Clin Oncol 2007;25(supplement):abstract 6512.